The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of facility case volume on overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era.
 
Yu-Wei Chen
No Relationships to Disclose
 
Katherine Tullio
No Relationships to Disclose
 
Moshe Chaim Ornstein
No Relationships to Disclose
 
Petros Grivas
Consulting or Advisory Role - AstraZeneca; Bayer; Biocept; Bristol-Myers Squibb; Clovis Oncology; Dendreon; EMD Serono; Exelixis; Genentech; Merck
Speakers' Bureau - Bristol-Myers Squibb; Genentech
Research Funding - AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncogenex (Inst); Pfizer (Inst)
 
Jorge A. Garcia
Consulting or Advisory Role - Bayer; Eisai; Exelixis; Genentech/Roche; Medivation; Pfizer; Sanofi
Speakers' Bureau - Bayer; Genentech/Roche; Medivation/Astellas; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Lilly (Inst); Orion (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Eisai; Exelixis; Genentech/Roche; Medivation/Astellas; Pfizer; Sanofi
 
Brian I. Rini
Consulting or Advisory Role - Corvus Pharmaceuticals; Merck; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Pfizer